Tsuchihashi, Kenji
Kusaba, Hitoshi
Yoshihiro, Tomoyasu
Fujiwara, Toshifumi
Setsu, Nokitaka
Endo, Makoto
Matsumoto, Yoshihiro
Imajima, Takashi
Shinohara, Yudai
Ito, Mamoru
Yamaga, Satoru
Tanoue, Kenro
Arimizu, Kohei
Ohmura, Hirofumi
Hanamura, Fumiyasu
Yamaguchi, Kyoko
Isobe, Taichi
Ariyama, Hiroshi
Nakashima, Yasuharu
Akashi, Koichi
Baba, Eishi
Funding for this research was provided by:
Japan Society for the Promotion of Science KAKENHI (20K07638)
Article History
Received: 8 June 2020
Accepted: 17 November 2020
First Online: 1 December 2020
Competing interests
: K.T. received honoraria from Eisai, Chugai Pharma and Novartis Pharma. N.S. received honoraria from Daiichi Sankyo. M.E. received honoraria from Eisai, Taisho, Daiichi Sankyo, Novartis Pharma and Taisho-Toyama. M.E. received consulting fee from Eli Lilly. Y.M. received honoraria from Eisai, Taiho Pharma, Synthes and Medtronic. M.T. received honoraria from Chugai Pharma and Japan Blood Product Organization. H.A. received honoraria from Chugai Pharma. Y.N. received honoraria from Chugai Pharmaceutical, Mitsubishi-Tanabe Pharma, Janssen Pharmaceutical, Pfizer, Eisai, AbbVie, Bristol-Myers Squibb, Astellas, AYUMI, Hisamitsu, Taisho Pharmaceutical, Takeda Pharmaceutical, Zimmer-Biomet and Kyocera. Y.N. received donation from Kyocera. K.A. received honoraria from Astellas Pharm, AbbVie GK, Eisai, Kyowa Kirin, Novartis Pharma, Bristol-Myers Squibb, Celgene, Janssen Pharma, Takeda Pharma, Chugai Pharma, Otsuka Pharma, Daiichi Sankyo, Amgen Astellas BioPharma and Ono Pharma. K.A. received donation from Astellas Pharma, Eisai, Sanofi, Asahi Kasei Pharma, Japan Blood Products Organization, Kyowa Kirin, Mochida Pharma, Ono Pharma, Otsuka Pharma, Shionogi, Yakult Honsh, Sumitomo Dainippon Pharma,Taiho Pharma, Daiichi Sankyo, Chugai Pharma, Nippon Kayaku, Nippon Shinyaku, Nihon Pharma, FUJIFILM Toyama Chemical, Takeda Pharma, Novartis Pharma, MSD and Eli Lilly Japan. E.B. received honoraria from Eli Lilly Japan. No other authors have no competing interests.